Precision BioSciences (DTIL) to Release Quarterly Earnings on Wednesday

Precision BioSciences (NASDAQ:DTIL) is expected to announce its earnings results before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of ($2.09) per share and revenue of $4.28 million for the quarter.

Precision BioSciences Price Performance

DTIL opened at $4.98 on Wednesday. The business has a fifty day moving average of $5.12 and a 200 day moving average of $6.79. Precision BioSciences has a 52-week low of $3.61 and a 52-week high of $15.97. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. The stock has a market cap of $38.20 million, a P/E ratio of 83.01 and a beta of 1.59.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on DTIL shares. BMO Capital Markets upgraded Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective for the company in a report on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Precision BioSciences in a report on Wednesday, February 19th.

Insider Buying and Selling at Precision BioSciences

In other news, insider J. Jefferson Smith sold 10,287 shares of the business’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $4.79, for a total value of $49,274.73. Following the completion of the transaction, the insider now directly owns 87,440 shares of the company’s stock, valued at approximately $418,837.60. The trade was a 10.53 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael Amoroso sold 36,838 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $4.67, for a total value of $172,033.46. Following the completion of the transaction, the chief executive officer now directly owns 107,087 shares of the company’s stock, valued at approximately $500,096.29. The trade was a 25.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders bought 8,734 shares of company stock valued at $39,946 and sold 47,279 shares valued at $222,064. 4.00% of the stock is currently owned by corporate insiders.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.